Uvidem Uses, Dosage, Side Effects and more
Uvidem is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
| Trade Name | Uvidem |
| Generic | IDD-3 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in melanoma.
How Uvidem works
Uvidem is well tolerated with evidence of efficacy and induction of immune response in patients with progressive metastatic melanoma.
